Preclinical absorption, distribution, metabolism, excretion, and pharmacokinetic–pharmacodynamic modelling of N-(4-(3-((3S,4R)-1-ethyl-3-fluoropiperidine-4-ylamino)-1H-pyrazolo[3,4-b]pyridin-4-yloxy)-3-fluorophenyl)-2-(4-fluorophenyl)-3-oxo-2,3-dihydropyridazine-4-carboxamide, a novel MET kinase inhibitor

Bianca M. LiedererGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA, USACorrespondence[email protected]

Leonid M. BerezhkovskiyGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA, USA

Brian J. DeanArray BioPharma, Inc., Drug Metabolism, Pharmacokinetics and Clinical Pharmacology, Boulder, CO, USA

Vikki DinkelArray BioPharma, Inc., Drug Metabolism, Pharmacokinetics and Clinical Pharmacology, Boulder, CO, USA

Jing PengGenentech, Inc., Translational Oncology, South San Francisco, CA, USA

Mark MerchantGenentech, Inc., Translational Oncology, South San Francisco, CA, USA

Emile G. PliseGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA, USA

Harvey WongGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA, USA

Xingrong LiuGenentech, Inc., Drug Metabolism and Pharmacokinetics, South San Francisco, CA, USA

Articles from other publishers (9)